Fig. 2

Results of the prospective observational study. a Frequency of EGFR driver (left), T790M mutation in all patients (middle) and T790M mutation in EGFR driver mutation positive patients in plasma (right) according to the treatment line of afatinib (first-line vs. second or subsequent EGFR-TKIs setting after gefitinib and/or erlotinib). b T790M mutation copy numbers in plasma as assessed using ddPCR. c Serial analysis for T790M mutation in plasma obtained from a patient who continued afatinib treatment after RECIST-PD. d T790M mutation status in plasma as assessed using ddPCR and in tissue samples in patients with T790M negative results using the cobas test